APP and Alzheimer disease: Thus, inhibition of BACE1 and/or γ-secretaseactivity might be an effective way for AD treatment by reducing Aβ production [34]–[36].Yetunder normal conditions, majority of APP protein are cleaved by α-secretase within the Aβ domain, generating a secreted N-terminal fragment (sAPPα) and a membrane-bound C-terminal fragment of 83 amino acids (C83) [37], [38], which excludes Aβ generation.